Corvus Pharmaceuticals, Inc

82 articles about Corvus Pharmaceuticals, Inc

• Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

  12/5/2022

  Corvus Pharmaceuticals, Inc. announced that it will host an investor conference call to provide an update on CPI-818 data that will be presented at the 64th American Society of Hematology Annual Meeting and Exposition, along with an update on the Company’s development programs.

• Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

  11/3/2022

  Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10-13, 2022.

• Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

  11/3/2022

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the third quarter ended September 30, 2022.

• Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

  10/27/2022

  Corvus Pharmaceuticals, Inc. announced that the Company will host a conference call and webcast on November 3, 2022 at 4:30 pm ET to provide a business update and report third quarter 2022 financial results.

• Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

  10/25/2022

  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).

• Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in ChinaMupadolimab clinical trial in China will be conducted by Angel Pharmaceuticals

  9/26/2022

  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application to initiate a Phase 1/1b clinical trial of mupadolimab (formerly CPI-006) has been approved by the Center for Drug Evaluation of the China National Medical Products Administration.

• Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place September 12-14, 2022.

• Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

  8/8/2022

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the second quarter ended June 30, 2022.

• Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022

  7/28/2022

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the Company will host a conference call and webcast on August 8, 2022 at 4:30 pm ET to provide a business update and report second quarter 2022 financial results.

• Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

  7/21/2022

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately.

• Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

  5/10/2022

  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, is hosting an R&D Symposium today in New York City.

• Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

  5/5/2022

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, provided a business update and reported financial results for the quarter ended March 31, 2022.

• Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York

  4/26/2022

  Corvus Pharmaceuticals, Inc. today announced that it will host an R&D Symposium to provide an update on the Company’s three clinical programs. The event will be held on Tuesday, May 10, 2022, in New York City from 9:00 – 11:30 am Eastern Time.

• Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

  3/10/2022

  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.

• Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

  3/3/2022

  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and webcast on March 10, 2022 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2021 financial results.

• Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China

  1/13/2022

  Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has treated the first patient in its Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

• New Preclinical Data Highlights Potential for CPI-818 (ITK Inhibitor) as a Therapy for Acute Graft Versus Host Disease in Patients Receiving Bone Marrow Transplantation

  12/13/2021

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced new preclinical data demonstrating the potential of CPI-818, the company’s ITK inhibitor, for the prevention and therapy of acute graft versus host disease in patients receiving allogeneic hematopoietic cell transplantation.

• Corvus Pharmaceuticals Presents Updated Data from Mupadolimab (Anti-CD73) Phase 1/1b Clinical Trial at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/12/2021

  Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), today announced updated results from its Phase 1/1b clinical trial of mupadolimab (formerly CPI-006), a humanized monoclonal antibody directed against CD73 with a proposed unique mechanism of activating B cells to generate immune responses to tumor antigens and viruses, and inhibiting the production of immunosuppressive adenosine in the tumor microenvironment.

• Corvus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

  11/10/2021

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will present at the Jefferies London Healthcare Conference, which is taking place November 16-19, 2021.

• Corvus Pharmaceuticals to Present Updated Mupadolimab (Anti-CD73) Data at 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/2/2021

  Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will present data from its Phase 1/1b trial of mupadolimab at the 2021 Society for Immunotherapy of Cancer Annual Meeting, taking place on November 10-14, 2021.